BBHC
GNMK

Brown Brothers Harriman & Co’s GenMark Diagnostics, Inc GNMK Stock Holding History

Brown Brothers Harriman & Co’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,735
Closed -$7K – 1265
2020
Q1 		$7K Buy
+1,735
New +$8.13K ﹤0.01% 763

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Brown Brothers Harriman & Co's GNMK Position: Q2 2020 in Review

Brown Brothers Harriman & Co sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 1,735 shares — an estimated $7K sold.

Brown Brothers Harriman & Co first reported a position in GNMK in Q1 2020 and held it in 1 quarter. The position peaked at $7K in Q1 2020. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

  • Brown Brothers Harriman & Co reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 1,735 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $7K.
  • Brown Brothers Harriman & Co first reported a position in GenMark Diagnostics, Inc in Q1 2020 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's GenMark Diagnostics, Inc position peaked at $7K in Q1 2020.
  • 148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2020, filed 13 Aug 2020.